Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
Table 1
Baseline characteristics of the patients (n = 17).
Variables
Mean ± SD/median (Q1-Q3)/n(%)
Age (years)
52.35 ± 12.82
Male
13 (76.47)
Smoking
9 (52.94)
BMI (kg/m2)
27.34 (25.39, 28.34)
Hypertension
9 (52.94)
Diabetes mellitus
3 (17.65)
Triglycerides (mmol/L)
1.61 (1.34, 2.32)
Total cholesterol (mmol/L)
4.95 (4.04, 5.36)
HDL cholesterol (mmol/L)
1.13 (1.00, 1.29)
LDL cholesterol (mmol/L)
2.81 (2.43, 3.50)
AI
3.10 (2.84, 3.55)
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AI, atherogenic index = (TC − HDL)/HDL.
